|
Jul 15
|
Bausch Health's Xifaxan Patent Clarity, Policy Commentary in Focus for Q2, RBC Says
|
|
Jul 12
|
Bausch Health Companies (BHC) Canada Announces Expanded Availability of CABTREO Gel
|
|
Jul 11
|
Chlamydia Market Analysis and Forecast, 2025-2035 Featuring ActivBiotics, Bausch Health, Allergan, WCG Clinical, Hologic, Evofem, CRMI, Meridian Bioscience, Pfizer
|
|
Jul 10
|
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
|
|
Jul 10
|
Bausch Health Appoints New Chief Accounting Officer
|
|
Jul 7
|
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
|
|
Jul 2
|
Bausch Health to Announce Second Quarter 2025 Results on July 30
|
|
Jun 27
|
Marriott Vacations, Bausch Health See Activist Actions
|
|
Jun 23
|
Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June
|
|
Jun 22
|
A Billionaire Trump Supporter Is Buying These Two Stocks
|
|
Jun 14
|
Bausch Health (BHC) Jumps 8.5% as Exec Hikes Stake; Subsidiaries Raise Over $3-Billion Fresh Funds
|
|
Jun 10
|
Bausch + Lomb Launching Senior Secured Notes Offering and Refinancing Credit Agreement
|
|
Apr 4
|
Bausch + Lomb's Q1 Earnings Expected in Line With Forecasts, RBC says
|
|
Apr 2
|
Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month
|
|
Mar 31
|
Bausch + Lomb recalls Envista intraocular lenses over safety risks
|
|
Mar 15
|
Bausch Health announces next steps in financining initiative
|
|
Mar 14
|
Bausch Health Announces Next Steps in Financing Initiative with J.P. Morgan
|
|
Feb 21
|
3 US Growth Companies With Up To 28% Insider Ownership
|
|
Feb 21
|
Why Bausch Health Companies Inc. (BHC) Went Up On Thursday?
|
|
Feb 20
|
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales
|